SCHEMBL4497139

SCHEMBL4497139

CC(C(=O)O)n1cc(-c2ccc(Cl)cc2)[nH]c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 3/20 0.41
THRB P10828 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
HPGD P15428 1/20 0.41
TYMP P19971 1/20 0.39
KMT2A Q03164 1/20 0.36
MAPT P10636 3/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MMP2 P08253 2/20 0.35
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35
TP53 P04637 1/20 0.35
MCL1 Q07820 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16664837 0.72 ALDH1A1 (0.51) ALDH1A1GAAKDM4ETHRBTDP1
SCHEMBL2446657 0.71 TYMP (0.44) ALDH1A1GAAKDM4ETYMPKMT2A
SCHEMBL3446839 0.71 ALDH1A1 (0.45) ALDH1A1GAAKDM4ETHRBTDP1
SCHEMBL4736668 0.71 RAB9A (0.51) ALDH1A1GAAKDM4EHPGDKMT2A
SCHEMBL8045280 0.69 HPGD (0.41) ALDH1A1HPGDTYMP
SCHEMBL3918612 0.68 ALDH1A1 (0.51) ALDH1A1GAAKDM4ETHRBTDP1
SCHEMBL8228882 0.68 KDM4E (0.50) ALDH1A1GAAKDM4ETHRBTDP1
SCHEMBL4513053 0.67 SLC6A9 (0.36) ALDH1A1HPGDTYMPKMT2ASLC6A9
SCHEMBL4508418 0.64 SLC6A9 (0.37) KMT2ASLC6A9
SCHEMBL3919676 0.64 DRD2 (0.56) ALDH1A1GAAKDM4ETHRBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084481-B2 Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-12-27 US disclosed
US-20090312381-A1 Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors BAYER HEALTHCARE AG (DE) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312381-A1 Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors AVPR2, AVPR1A, AVPR1B ALDH1A1 2276/4885GAA 3599/4885KDM4E 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.